#Reyataz

Bristol Myers Squibb agrees to pay $11 million. The 2019 class-action lawsuit filed by AIDS activists includes several other drugmakers.

Gilead Sciences presented findings from several studies of the single-tablet antiretroviral regimen at a recent scientific meeting.

A major plus of the implant is that it can be easily removed if necessary.

The indication for AbbVie’s regimen includes those with compensated cirrhosis.

Currently, Gilead Sciences’ HIV regimen is not approved to treat drug-resistant virus.

More high-quality evidence is needed to determine how this class of HIV medications may affect weight gain.

Among those taking Epivir, taking two antiretrovirals instead of three was tied to fewer people stopping because of side effects.

Janssen’s single-tablet antiretroviral regimen was approved on July 17.

This connection remained even when researchers took into account various risk factors for cardiovascular disease.

Most of such drug resistance seen is to older drugs.

That’s compared with HIV-negative men.

A recent study compared birth outcomes among HIV-positive women exposed to various antiretroviral regimens.

Investigators behind the recent study that raised this concern suggest not combining the two until more research can be done.

A recent analysis of Europeans taking boosted protease inhibitors for HIV treatment found this pair prompted the best long-term response.

This marks the manufacturer’s fifth generic antiretroviral launch.